FDA delays decision on Novartis’ potential blockbuster MS drug, wiping away priority review
So much for a speedy review.
In February, Novartis announced that an application for their much-touted multiple sclerosis drug ofatumumab had been accepted and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
